Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Cyclophosphamide

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Early Phase 1 (1)
Phase 2 (1)

Trial Status

Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07586709Early Phase 1RecruitingPrimary

In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

NCT07777406RecruitingPrimary

Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma

NCT01350245Phase 2Completed

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Showing all 3 trials

Research Network

Common Treatments

  • Cyclophosphamide1
  • Donor Lymphocyte Infusion Dli1
  • Tacrolimus1
  • Total Body Irradiation Tbi1
  • In Vivo Bcmagprc5d Tandem Dual Cart Cell1

Active Sponsors

  • Università degli Studi 'G. d'Annunzio' Chieti e Pescara1
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University1
  • Liping Dou1

Top Investigators

Related Conditions

  • Lymphoma1
  • Chronic Myeloid Leukemia1
  • Myelodysplastic Syndromes1
  • Acute Lymphocytic Leukemia1
  • Acute Myeloid Leukemia1

Activity Timeline